We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 52.00 | 0.43% | 12,222.00 | 12,218.00 | 12,222.00 | 12,234.00 | 12,114.00 | 12,114.00 | 124,483 | 09:01:59 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.86 | 189.74B |
From May 2019 to May 2024
By Ed Ballard
LONDON--British-Swedish drugmaker AstraZeneca PLC (AZN.LN) said Thursday it received approval from the U.S. Food and Drug Administration for Xigduo XR as a daily treatment for type 2 diabetes.
"The addition of Xigduo XR to our U.S. diabetes portfolio is further evidence of AstraZeneca's commitment to develop new treatment options for patients with type 2 diabetes," said Elisabeth Björk, head of Cardiovascular & Metabolism at AstraZeneca's Global Medicines Development arm.
The drug, a combination of glucose-lowering agents dapagliflozin and metformin hydrochloride, has already been approved in Australia for adults with the condition.
Write to Ed Ballard at ed.ballard@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
